The RECOVERY trial independent Data Monitoring Committee reviewed the safety and efficacy data that were available today for the 15,545 patients randomised, including 325 patients recruited in the REGN-COV2 versus control comparison. In the light of these data and the available external information, the Committee concluded that there was no cogent reason to modify the protocol or intake to the study, and that recruitment of eligible patients to all arms of the trial should continue. 

Professor Peter Horby and Professor Martin Landray, Co-leads, RECOVERY trial